PPT-ASCO 2012 Review Gynecologic Cancer

Nelson Teng MD PhD Director Gynecologic Oncology Stanford University School of Medicine Disclosures I do not have any conflict of interest to report Acknowledgement Dr Jakob Dupont. . Highlights from the Annual Clinical Meeting. Gynecologic Cancer. Sidney A. Scudder, MD. Professor of Medicine. U.C. Davis Cancer Center. Conference Directors:. Helen Chew, MD, FACP. Primo Lara, Jr., MD. Gastrointestinal Malignancies. Thomas J. Semrad MD, MAS. Assistant Professor of Medicine. Division of Hematology/Oncology. Disclosure. Speaker’s Bureau: Novartis. Consulting: Amgen, Genomic Health. Magee-. Womens. Hospital of UPMC. Clinical and Research Updates in Gynecologic Oncology. Gynecologic Cancer in the United States. American Cancer Society, 2017. New Cases. Cancer Deaths. Ovary. 22,440. A Centers for Disease Control and Prevention Campaign. What We Will Discuss. Part I. What You Need to Know About Gynecologic Cancers. Part II: Recognizing the Warning Signs. Part III: Prevention, Screening, and Treatment. Protocol GOG-0258. Louise E. Francis, B.S., CMD. Gynecologic Oncology Group. . (GOG). The only National Cancer Institute funded cooperative group. . in the US currently conducting trials 0n gynecologic cancers. Ignace Vergote MD PhD FACS FSPS. Chairman, Leuven Cancer . Institute. . and . Dept. Ob& . Gyn. , Leuven. , European Union. Ovarian Carcinoma: . Classical Evolution of the disease. Symptoms. (Late) Diagnosis. The George W. Morley Professor University of Michigan What is gynecologic cancer? begin in the female reproductive organs. The most common gynecologic cancers are endometrial cancer, ovarian cancer an reproductive organs: cervical, ovarian, uterine, vaginal, and vulvar. As a group, they are referred to as gynecologic (GY-neh-kuh-LAH-jik) cancer. (A sixth type of gynecologic cancer is the very rare the development research projects and educational the past at an the management malignant neoplasm requires a multi- disciplinary approach, which includes Gynecologic Oncology years. During subspecial Department of Obstetrics and Gynecology ________________________________________________________________________________________________________Division of Gynecologic OncologyEducationProgram for Fel cancer: Immunotherapy. Oscar Arrieta MD. Thoracic. . Oncology. . Unit. . National. . Cancer. . Institute. of . Mexico. The Immunoediting Hypothesis: . Understanding Patterns of Response. Reprinted by permission from MacMillan Publishers Ltd: [Nat . N=5. Mean=8.6 . SD=19.5. N=53. Mean=15.6 . SD=19.6. N=52. Mean=26.8 . SD=47.3. N=288. Mean=21.1 . SD=28.1. N=283. Mean=12.2 . SD=14.5. N=293. N=292, Mean=33.9, SD=50.34. N=275, Mean=31.7, SD=26.3. N=245. 2,3. Emily V. Dressler, PhD. 4. ; David I. Shalowitz, MD, MSHP. 1,2.  . 1 . Section on Gynecologic Oncology, Department of Obstetrics and . Gynecology, . 2 . Department of Implementation . Science, . Amy Klapheke, MPH, PhD. Public Health Institute, Cancer Registry of Greater California. NAACCR/IACR Combined Annual Conference. June 11, 2019. Outline. Background. Methods. Results. Discussion. Background.